Guest posting: Assoc. Prof. Josh Davis, President, Australasian Society for Infectious Diseases. @Guru_JoshD “ID week” is a large US infectious diseases conference; this year it was in San Francisco, and had over 8,000 delegates. The most talked about trial at this conference (mentioned in at least 5 different sessions) was the Australian-led MERINO trial, an […]
Guest posting : Dr Jonathan Ash, Advanced training registrar, John Hunter Hospital. Ventriculitis is a rare but potentially disastrous complication of external ventricular drain placement, and with increasing rates of multi-drug resistant organisms, effective parenteral antibiotic choices are limited. Colistin has an established role in the treatment of infections caused by MDR Gram negatives, particularly […]
SITUATION Due to a global shortage, many Hunter New England Local Health District sites have low supplies of piperacillin+tazobactam with shortages likely until after September. It is essential that further use of this agent is conserved as below. Amoxycillin+clavulanate is now available in a parenteral form and is a suitable option in many circumstances, contingent on local […]
Guest post: Dr Rod Givney, Pathology North Microbiologist. How well do you know these commonly used drugs, their pros and cons? Here is an up-to-date overview prepared for our advanced trainee tutorial series. Nitroimidazoles overview 2017 Givney.
The Special Access Scheme (SAS) allows practitioners to import/gain access to therapeutic goods currently not registered on the Australian Register of Therapeutic Goods (ARTG) for a single patient on a case by case basis. Fosfomycin (one such SAS drug) is a broad spectrum antibiotic belonging to the phosphonic acid derivative drug class (other examples in this drug class include foscarnet and adefovir).
Our JMO pre-test survey also asked “What puzzles you about antibiotics and their use”. A recurring theme was concern about remembering the various classes and names of antibiotics. Here are some useful pointers and a short quiz !
Q2 in our JMO pre-test asked: “What is the main mechanism by which the bacterium Staphylococcus aureus becomes resistant to penicillin?” We gave alternatives enumerating basic mechanisms that micro-organisms use (often in combination) to become resistant to an antimicrobial agent (graphic below). Production of penicillinase (i.e. inactivation by a type of beta-lactamase) was the correct answer– more […]
The antibiotic knowledge survey of our new interns this week, showed that many were confused about which class vancomycin (a glycopeptide) fell into (30% thought it was an aminoglycoside). This is a potentially dangerous confusion as the dosing, side effects and monitoring all differ substantially between these classes: Aminoglycoside Glycopeptide Indicative agents Gentamicin Vancomycin Dosing […]
Antibiotics are consistently and widely used in almost all areas of clinical healthcare in Australia with 38% of hospital patients being treated with a microbial on any given day (2014) and 46% of the general population being dispensed at least one systemic antimicrobial prescription in the community (2014-2015). Do you think you’ve got a […]
A frequent issue is deciding whether a patient with a “penicillin allergy” can safely be given a cephalosporin antibiotic – what is the real risk of cross reaction and is it much less for third generation agents such as ceftriaxone? A recent publication in Prescriber Update from Medsafe New Zealand succinctly analyses cross-reactivity amongst beta-lactam antibiotics in the light […]